Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis Pulling Out All The Stops To Amp Up Entresto Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has set a sales goal of $200m for Entresto in 2016, not an enormous amount for a drug that is expected to eventually be a multi-billion dollar seller, but ambitious given its slow first quarter start.

Advertisement

Related Content

2Q Pharma Results Preview: What Lies Ahead
Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel